165 related articles for article (PubMed ID: 31452949)
1. Association between p62 expression and clinicopathological characteristics in oral leukoplakia.
Yoshida T; Terabe T; Nagai H; Uchida F; Hasegawa S; Nagao T; Miyabe S; Ishibashi-Kanno N; Yamagata K; Warabi E; Gosho M; Yanagawa T; Bukawa H
Clin Exp Dent Res; 2019 Aug; 5(4):389-397. PubMed ID: 31452949
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical study of syndecan-1 down-regulation and the expression of p53 protein or Ki-67 antigen in oral leukoplakia with or without epithelial dysplasia.
Kurokawa H; Matsumoto S; Murata T; Yamashita Y; Tomoyose T; Zhang M; Fukuyama H; Takahashi T
J Oral Pathol Med; 2003 Oct; 32(9):513-21. PubMed ID: 12969225
[TBL] [Abstract][Full Text] [Related]
3. Accumulation of the p53 tumor-suppressor gene product in oral leukoplakia.
Wood MW; Medina JE; Thompson GC; Houck JR; Min KW
Otolaryngol Head Neck Surg; 1994 Dec; 111(6):758-63. PubMed ID: 7527509
[TBL] [Abstract][Full Text] [Related]
4. [Clinicopathological characteristics of malignant transformation in 85 cases of oral leukoplakia].
Gao Y; Guo ZL; Luo HY; Wang J
Zhonghua Kou Qiang Yi Xue Za Zhi; 2012 Jul; 47(7):410-3. PubMed ID: 22931571
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of p53 and p63 in oral squamous cell carcinoma, oral leukoplakia, and oral submucous fibrosis.
Varun BR; Ranganathan K; Rao UK; Joshua E
J Investig Clin Dent; 2014 Aug; 5(3):214-9. PubMed ID: 23776093
[TBL] [Abstract][Full Text] [Related]
6. Changes in apoptosis and mitotic index, p53 and Ki67 expression in various types of oral leukoplakia.
Kövesi G; Szende B
Oncology; 2003; 65(4):331-6. PubMed ID: 14707453
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of cornulin, keratin 4, keratin 13 expression and grade of dysplasia for predicting malignant progression of oral leukoplakia.
Schaaij-Visser TB; Bremmer JF; Braakhuis BJ; Heck AJ; Slijper M; van der Waal I; Brakenhoff RH
Oral Oncol; 2010 Feb; 46(2):123-7. PubMed ID: 20036603
[TBL] [Abstract][Full Text] [Related]
8. 8-Nitroguanine formation in oral leukoplakia, a premalignant lesion.
Ma N; Tagawa T; Hiraku Y; Murata M; Ding X; Kawanishi S
Nitric Oxide; 2006 Mar; 14(2):137-43. PubMed ID: 16290060
[TBL] [Abstract][Full Text] [Related]
9. Podoplanin expression as a predictive marker of dysplasia in oral leukoplakia.
Gissi DB; Gabusi A; Tarsitano A; Luccarini L; Morandi L; Montebugnoli L
J Craniomaxillofac Surg; 2018 May; 46(5):759-764. PubMed ID: 29588189
[TBL] [Abstract][Full Text] [Related]
10. Oral premalignant lesions: from a clinical perspective.
Amagasa T; Yamashiro M; Uzawa N
Int J Clin Oncol; 2011 Feb; 16(1):5-14. PubMed ID: 21225307
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of p53 and bcl-2 oncoprotein expression in precancerous lesions of the oral cavity.
Sulkowska M; Famulski W; Chyczewski L; Sulkowski S
Neoplasma; 2001; 48(2):94-8. PubMed ID: 11478700
[TBL] [Abstract][Full Text] [Related]
12. E-cadherin as a potential biomarker of malignant transformation in oral leukoplakia: a retrospective cohort study.
von Zeidler SV; de Souza Botelho T; Mendonça EF; Batista AC
BMC Cancer; 2014 Dec; 14():972. PubMed ID: 25518919
[TBL] [Abstract][Full Text] [Related]
13. Nuclear localization of beta-catenin involved in precancerous change in oral leukoplakia.
Ishida K; Ito S; Wada N; Deguchi H; Hata T; Hosoda M; Nohno T
Mol Cancer; 2007 Oct; 6():62. PubMed ID: 17922924
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of p62/SQSTM1 subcellular localization and LC3B in oral squamous cell carcinoma.
Liu JL; Chen FF; Lung J; Lo CH; Lee FH; Lu YC; Hung CH
Br J Cancer; 2014 Aug; 111(5):944-54. PubMed ID: 24983366
[TBL] [Abstract][Full Text] [Related]
15. Incorporation of differentiated dysplasia improves prediction of oral leukoplakia at increased risk of malignant progression.
Wils LJ; Poell JB; Evren I; Koopman MS; Brouns EREA; de Visscher JGAM; Brakenhoff RH; Bloemena E
Mod Pathol; 2020 Jun; 33(6):1033-1040. PubMed ID: 31896811
[TBL] [Abstract][Full Text] [Related]
16. LAMC2 is a predictive marker for the malignant progression of leukoplakia.
Nguyen CT; Okamura T; Morita KI; Yamaguchi S; Harada H; Miki Y; Izumo T; Kayamori K; Yamaguchi A; Sakamoto K
J Oral Pathol Med; 2017 Mar; 46(3):223-231. PubMed ID: 27529842
[TBL] [Abstract][Full Text] [Related]
17. Carcinoma and dysplasia in oral leukoplakias in Taiwan: prevalence and risk factors.
Lee JJ; Hung HC; Cheng SJ; Chen YJ; Chiang CP; Liu BY; Jeng JH; Chang HH; Kuo YS; Lan WH; Kok SH
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Apr; 101(4):472-80. PubMed ID: 16545712
[TBL] [Abstract][Full Text] [Related]
18. Oral leukoplakia: A clinicopathological study and malignant transformation.
Tovaru S; Costache M; Perlea P; Caramida M; Totan C; Warnakulasuriya S; Parlatescu I
Oral Dis; 2023 May; 29(4):1454-1463. PubMed ID: 34982498
[TBL] [Abstract][Full Text] [Related]
19. DNA damage through oxidative stress is an important event in oral leukoplakia.
Barros CCDS; Freitas RA; Miguel MCDC; Dantas da Silveira ÉJ
Arch Oral Biol; 2022 Mar; 135():105359. PubMed ID: 35121264
[TBL] [Abstract][Full Text] [Related]
20. Alterations of rb pathway components are frequent events in patients with oral epithelial dysplasia and predict clinical outcome in patients with squamous cell carcinoma.
Soni S; Kaur J; Kumar A; Chakravarti N; Mathur M; Bahadur S; Shukla NK; Deo SV; Ralhan R
Oncology; 2005; 68(4-6):314-25. PubMed ID: 16020958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
